Loading...
| Name | Option type | Quality (1-5)↓ | Topics | Created | |
|---|---|---|---|---|---|
Will Incyte's stock price increase by at least 10% following the Tafasitamab study results by December 31, 2024?  | Binary | 3 | 4 months ago | ||
What will be Incyte's market share in the oncology market by December 31, 2025? | Categorical | 3 | 4 months ago | ||
Will Tafasitamab receive FDA approval for relapsed or refractory follicular lymphoma by August 15, 2025? | Binary | 2 | 4 months ago | ||
Will Tafasitamab be included in NCCN guidelines for follicular lymphoma by December 31, 2024? | Binary | 2 | 4 months ago | ||
How many new indications will be approved for Tafasitamab by the FDA by December 31, 2025? | Categorical | 2 | 4 months ago | ||
What will be the revenue generated by Tafasitamab in 2025? | Categorical | 2 | 4 months ago |